“…Recent studies have shown that altered expression of DDX58 [413], STAT1 [414], TLR4 [415], CYP2D6 [416], JAK2 [417], TLR2 [418], DUSP6 [419], HDAC9 [420], LATS2 [421], CA2 [150], HIPK3 [422], CCR2 [423], GAB1 [120], UFL1 [424], OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) [425], PRKAR1A [265], SIRT1 [426], FGL2 [427], TET2 [428], ASCC2 [429], BIN1 [430], HSPB1 [431], IGFBP4 [432], TRPM4 [433] and LGALS3 [434] might be associated with the progression of heart failure. STAT1 [435], TLR4 [436], ABCA1 [437], PTGS2 [68], CYP2D6 [438], CR1 [439], PDK4 [440], RNF213 [441], ZDHHC17 [70], TLR8 [442], PDGFC (platelet derived growth factor C) [443], TLR2 [444], CYP1B1 [445], HDAC9 [446], IL1RN [447], GCH1 [448], EGR1 [449], ZEB2 [450], PLA2G7 [451], CCR2 [452], GCLC (glutamate-cysteine ligase catalytic subunit) [258], VEGFA (vascular endothelial growth factor A) [453], CD46 [454], NFKBIZ (NFKB inhibitor zeta) [455], LDLR (low density lipoprotein receptor) [456], TLR6 [457], SIRT1 [458], NOD2 [459], FGL2 [460], IDH1 [461], TET2 [462], PFKFB2 [463], KDM6A [464], IKZF2 [465], ZNF606 [466], PF4 [467], CCR7 [468], RUNX3 [469], TCF7 [470], PPBP (pro-platelet basic protein) [471], IGFBP4 [280], HSPG2 [472] and LGALS3 [236] expression might be regarded as an indicator of susceptibility to CAD. STAT1 [473], TLR4 [367], JAK2 [474], PDGFC (platelet derived growth factor C) […”